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world. Melanoma is a malignant tumor of melanocytes predominately of skin, but also found in the digestive
tract and eye. Its occurrence is statistically less than other forms of skin cancer, but corresponds to the highest
mortality. Surgical resection, in its early stages, is the only proven curative treatment. Metastatic disease is
incurable in most patients due to its refractibility to systemic cancer treatment. There are currently a large
number of treatment regimens in clinical use, and also ongoing clinical trials. The problem with currently
available regimens relates to the high cost and relative toxicities. However, in the last decade, trials utilizing
adoptive transfer of lymphocytes after host lymphodepletion via chemotherapy, have demonstrated objective
cancer regression in human patients with metastatic melanoma.
Methods: The focus of this study was to review the current literature for the last 10 years on all studies
pertaining to Adoptive Cell Transfer in treating metastatic melanoma. Electronic databases (Ovid – Medline,
Pub-Med, MD Consult, NIH) were utilized. There were no gender or age restrictions. Only studies published
in English were reviewed.
Results: Four clinical studies were chosen for this review in which patients with refractory metastatic
malignant melanoma were treated with varying doses of lymphdepleting chemotherapy and ACT. Variables
within each study were manipulated as to ascertain response changes, but the primary treatment remained the
same. Favorable clinical response was observed in a minority of patients in each study, but because of the
experimental nature of this method of treatment, overall outcomes continue to fluctuate.
Conclusion: This new form of epithelial cancer treatment is just in its infancy. With each consecutive research
trial, advances continue to be made. Melanoma is the deadliest of all skin cancers. With advances being made
daily in cellular engineering, it is only a matter of time before we have an effective form of ACT treatment for
malignant melanoma.
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Abstract   
 
Introduction: Malignant melanoma, the most aggressive of all skin cancers, is on the increase 
throughout the world. Melanoma is a malignant tumor of melanocytes predominately of skin, but 
also found in the digestive tract and eye. Its occurrence is statistically less than other forms of 
skin cancer, but corresponds to the highest mortality. Surgical resection, in its early stages, is the 
only proven curative treatment. Metastatic disease is incurable in most patients due to its 
refractibility to systemic cancer treatment. There are currently a large number of treatment 
regimens in clinical use, and also ongoing clinical trials. The problem with currently available 
regimens relates to the high cost and relative toxicities. However, in the last decade, trials 
utilizing adoptive transfer of lymphocytes after host lymphodepletion via chemotherapy, have 
demonstrated objective cancer regression in human patients with metastatic melanoma.  
 
Methods: The focus of this study was to review the current literature for the last 10 years on all 
studies pertaining to Adoptive Cell Transfer in treating metastatic melanoma. Electronic 
databases (Ovid – Medline, Pub-Med, MD Consult, NIH) were utilized. There were no gender or 
age restrictions. Only studies published in English were reviewed.  
 
Results: Four clinical studies were chosen for this review in which patients with refractory 
metastatic malignant melanoma were treated with varying doses of lymphdepleting 
chemotherapy and ACT. Variables within each study were manipulated as to ascertain response 
changes, but the primary treatment remained the same. Favorable clinical response was observed 
in a minority of patients in each study, but because of the experimental nature of this method of 
treatment, overall outcomes continue to fluctuate.  
 
Conclusion:  This new form of epithelial cancer treatment is just in its infancy. With each 
consecutive research trial, advances continue to be made. Melanoma is the deadliest of all skin 
cancers. With advances being made daily in cellular engineering, it is only a matter of time 
before we have an effective form of ACT treatment for malignant melanoma.  
 
KEYWORDS:  Adoptive Cell Transfer, Chemotherapy, Melanoma, Treatment, Immunotherapy 
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Adoptive Cell Transfer and Lymphdepleting Chemotherapy 
for the Treatment of Metastatic Melanoma 
 
Introduction 
 
Malignant melanoma (MM) develops due to changes in the melanocyte cells that produce 
melanin pigment. Melanocytes are most commonly found within the skin, but are also present in 
the uveal tract, upper digestive tract, anal canal, rectum, and vagina. One in six Americans will 
develop skin cancer at some point in their life.1 Skin cancer accounts for one third of all cancers 
in the United States.1 Around 160,000 new cases of melanoma are diagnosed worldwide each 
year.2 MM is more common in Caucasian populations living in sunny climates than in other 
groups.3 According to a World Health Organization report, about 48,000 melanoma related 
deaths occur worldwide per year.4 Fortunately, most patients with skin cancer develop non-
melanoma lesion(s), and mortality secondary to these lesions is rare. Metastatic Malignant 
Melanoma (MMM), however, accounts for 75% of all deaths associated with skin cancer.1  
In contrast to non-melanoma skin cancer (basal cell and squamous cell carcinoma), which 
typically affects older individuals, the frequency of MM peaks between 20 and 45 years of age.5 
Mortality rates are higher in men than in women.5 This occurrence is likely due to unrecognized 
lesions which develop in less easily observed areas, such as the back in men, and the dorsal leg 
in women (Figure I). Mortality is also increased in blacks, as is the propensity to develop more 
aggressive tumors and to be diagnosed at later stages.6 
Almost all malignant melanomas start with altering the color and appearance of normal-
looking skin. The area may be an abnormally darkly pigmented nevus, a new nevus, or one that 
has recently changed. It can be very difficult to distinguish the difference between a malignant 
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melanoma and a normal nevus. When looking for danger signs in pigmented lesions of the skin, 
the “ABCDE” mnemonic is utilized (Table I):  Asymmetry – Melanomas most likely have an 
irregular or asymmetrical shape. Typical nevi are usually symmetrical. Border – Melanomas 
may have poorly defined borders or ridged edges. Normal nevi have defined smooth edges. 
Color – Melanomas have many colors. They may contain a few different shades such as brown 
mixed with black, red, pink, white or a bluish tint. Normal nevi are regularly one shade of brown. 
Diameter – Most melanomas are more than 7mm in diameter, but many patients have been 
diagnosed with lesions much smaller. Evolving (changing) – Nevi may change in their size, 
shape or color which is a vital sign of malignant melanoma.7  
 Features that affect prognosis are, tumor thickness in millimeters (Breslow's depth:  Table 
III), depth related to skin structures (Clark level: Table III), type of melanoma, presence of 
ulceration, presence of lymphatic/perineural invasion, location of lesion, presence of satellite 
lesions, and presence of regional or distant metastasis.8 
 Certain types of melanoma have worse prognoses but this is explained by their thickness. 
Interestingly, superficial melanomas even with lymph node metastases carry a better prognosis 
than deep melanomas without regional metastasis at the time of staging. The presence of tumor 
infiltrating lymphocytes at the site of the lesion has also been correlated to an improved 
prognosis. Local recurrences tend to behave similarly to a primary lesion unless they are at the 
site of a wide local excision (as opposed to a staged excision or punch/shave biopsy) since these 
recurrences tend to indicate lymphatic invasion.8 
 When a melanoma spreads to a lymph node, one of the most important factors is the 
number of nodes affected. Extent of malignancy within a node is also important; 
micrometastases in which malignancy is only microscopic have a more favorable prognosis than 
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macrometastases. In some cases micrometastases may only be detected by special staining, and if 
malignancy is only detectable by a rarely-employed test known as the polymerase chain reaction 
(PCR), the prognosis is even better. Macrometastases in which malignancy is clinically apparent 
(in some cases the cancer may completely encompass a node) have a far worse prognosis, and if 
nodes are matted or if there is extracapsular extension, the prognosis is dire.9 
 When there is distant metastasis, the cancer is generally considered incurable. The five 
year survival rate is less than 10%. The median survival is 6 to 12 months. Treatment is 
palliative, focusing on life-extension and quality of life. In some cases, patients may live many 
months or even years with metastatic melanoma. Metastases to skin and lungs have a better 
prognosis, while metastases to brain, bone, and liver are more difficult to treat.9  
 There is not enough definitive evidence to adequately stage, and thus give a prognosis for 
ocular melanoma and melanoma of soft parts, or of mucosal melanomas (like rectal melanoma), 
although these tend to metastasize more aggressively. Even though regression may increase 
survival, when a melanoma has regressed, it is impossible to know its original size and thus the 
original tumor is often more widespread than a pathology report might indicate.9 
 Sometimes the skin lesion may bleed, itch, or ulcerate, although this is a very late sign. A 
slow-healing lesion should be watched closely, as that may be a sign of melanoma. Be aware 
also that in circumstances that are still poorly understood, melanomas may "regress" or 
spontaneously become smaller or invisible - however the malignancy is still present.9 
Genetics 
Familial melanoma is genetically heterogeneous,10 and loci for familial melanoma have 
been identified on the chromosome arms 1p, 9p and 12q. Multiple genetic events have been 
related to the pathogenesis of melanoma.11 The multiple tumor suppressor 1 (CDKN2A/MTS1) 
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gene encodes p16INK4a - a low-molecular weight protein inhibitor of cyclin-dependent protein 
kinases (CDKs) - which has been localized to the p21 region of human chromosome 9.12 
Currently, melanomas are diagnosed only after they become visible on the skin. In the future, 
however, physicians will hopefully be able detect melanomas based on a patient’s genotype, not 
just his or her phenotype. Recent genetic advances promise to help identify people with high-risk 
genotypes and to determine which of a person’s lesions have the greatest chance of becoming 
cancerous. A number of rare mutations, which often run in families, are known to greatly 
increase one’s susceptibility to melanoma. People with mutations in the MC1R gene, for 
example, are two to four times more likely to develop melanoma than those with two wild-type 
copies of the gene. MC1R mutations are very common; in fact, all people with red hair have a 
mutated copy of the gene. In addition to identifying high-risk patients, researchers also want to 
identify high-risk lesions within a given patient. Many new technologies, such as optical 
coherence tomography (OCT), are being developed to accomplish this. OCT allows pathologists 
to view 3-D reconstructions of the skin and offers more resolution than past techniques could 
provide.12 
Prevention 
Minimizing exposure to sources of ultraviolet radiation is necessary for prevention of 
malignant melanoma. There is a health campaign slogan in Australia which states “Slip-Slop-
Slap”. The goal of this country’s most recognized health message is to have people slip on a 
shirt, slop on sunscreen, and slap on a hat.  
In the past, it was recommended that people use sunscreens with an SPF rating of 30 or 
higher on exposed areas as older sunscreens more effectively blocked UVA with higher SPF. 
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Currently, newer sunscreen ingredients (avobenzone, zinc, and titanium) effectively block both 
UVA and UVB even at lower SPFs. However, there are questions about the ability of sunscreen 
to prevent melanoma. This controversy is discussed in numerous review articles, but 
dermatologists continue to take the position that the use of sun screen of at least 30 SPF is 
necessary.13 This correlation might be due to the confounding variable that individuals who used 
sunscreen to prevent burn might have a higher lifetime exposure to either UVA or UVB.  
Tanning, once believed to help prevent skin cancers, actually can lead to increase 
incidence of melanomas.13 Even though tanning beds emit mostly UVA, which causes tanning, it 
by itself might be enough to induce melanomas. This risk factor should be stressed to patients 
who frequently bask under the bulbs. 
A good rule of thumb for decreasing ultraviolet light exposure is to avoid the sun 
between the hours of 9 a.m. and 3 p.m during the summer solstice, or to avoid the sun when your 
shadow is shorter than your height. These are rough rules, however, and can vary depending on 
locality and individual skin cancer risk.13 
Treatment 
Surgery is the first choice therapy for localized cutaneous melanoma. Depending on the 
stage, a sentinel lymph node biopsy is done as well. Treatment of advanced malignant melanoma 
is performed with a multidisciplinary approach. 
Complete surgical excision with adequate margins and assessment for the presence of 
detectable metastatic disease along with aggressive follow up is standard.14 The surgery involves 
making a wide local excision (WLE) with 1 to 2 cm margins. Melanoma-in-situ is treated with 
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narrower surgical margins, usually 0.2 to 0.5 cm. Many surgeons consider 0.5 cm the standard of 
care for excision of melanoma-in-situ, but 0.2 cm margins might be acceptable for margin 
controlled surgery such as Mohs’ micrographic surgery.14 The WLE aims to reduce the rate of 
tumor recurrence at the site of the original lesion. This is a common pattern of treatment failure 
in melanoma. Following definitive diagnosis of melanoma, Mohs’ surgery has been reported 
with cure rate as low as 77% and as high as 98% for melanoma-in-situ.14,15 Failure to remove 
sufficient tissue due to incorrect margins is a common reason for treatment failure in malignant 
melanoma. 
Melanomas which spread usually do so to the lymph nodes in the region of the tumor 
before spreading elsewhere. Attempts to improve survival by removing lymph nodes surgically 
(lymphadenectomy) were associated with many complications but unfortunately with no overall 
survival benefit.16 Recently the technique of sentinel lymph node biopsy has been developed to 
reduce the complications of lymph node surgery while allowing assessment of the involvement 
of nodes with tumor.16  
Although controversial and without prolonging survival, sentinel lymph node (SLN) 
biopsy is often performed, especially for T1b/T2+ tumors, mucosal tumors, ocular melanoma, 
and tumors of the limbs.17 A process called lymphoscintigraphy is performed in which a 
radioactive tracer is injected at the tumor site in order to localize the sentinel nodes. Further 
precision is provided using a blue tracer dye and surgery is performed to biopsy the nodes. 
Routine haematoxylin and eosin staining, and immunoperoxidase staining are adequate to rule 
out node involvement.17 Polymerase chain reaction (PCR) tests on nodes, usually performed to 
test for entry into clinical trials, now demonstrate that many patients with a negative SLN 
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actually had a small number of positive cells in their nodes. Alternatively, a fine-needle 
aspiration may be performed and is often used to test masses.18 When a lymph node displays 
malignancy, a radical lymph node dissection will often be performed. If the disease is completely 
resected, the patient will be considered for adjuvant therapy.17 
Adjuvant treatment 
High risk melanomas typically require adjuvant treatment. In the United States most 
patients in otherwise good health, will begin up to a year of high-dose interferon treatment, 
which has severe side effects but may improve the patients’ prognosis.19 This claim is not 
supported by all research at this time, and in Europe interferon is usually not used outside the 
scope of clinical trials.20, 21 
 Metastatic melanomas can be detected by X-rays, CT scans, MRIs, PET and PET/CTs, 
ultrasound, LDH testing, and photo-acoustic detection.22  Lactate dehydrogenase (LDH) tests are 
also often used to screen for metastases, although many patients with metastases, even end-stage, 
have a normal LDH. Extraordinarily high LDH often indicates metastatic spread of the disease to 
the liver.22 
 Various chemotherapy agents are used, including dacarbazine (also termed DTIC), 
immunotherapy (with interleukin-2 (IL-2) or interferon (IFN)) as well as local perfusion are used 
by different centers. They can occasionally show dramatic success, but the overall success in 
metastatic melanoma is quite limited.23 IL-2 (Proleukin) is the first new therapy approved for the 
treatment of metastatic melanoma in 20 years. Studies have demonstrated that IL-2 offers the 
possibility of a complete and long-lasting remission in this disease, although only in a small 
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percentage of patients.24 A number of new agents and novel approaches are under evaluation and 
show promise.25  
 On June 23, 2008, Israeli scientists from the Oncology Institute of the Hadassa Medical 
Center in Jerusalem announced, that they had developed a vaccine by utilizing tumor surface 
antigens to stimulate the patient’s own immune response. This therapy apparently prevented 
recurrences of the disease among those in remission, and displayed increased survival for 
patients with active disease.  
Recent Approaches in Treatment 
 Experimental treatment developed at the National Cancer Institute (NCI), part of the 
National Institutes of Health in the US, was used in advanced (metastatic stage III/IV) 
melanoma, with moderate success. The treatment is adoptive transfer of genetically altered 
autologous lymphocytes which are reintroduced into the patient following a course of 
lymphodepleting chemotherapy. After manipulation and re-population, the lymphocytes 
recognize and bind to tumor-associated antigens (TAA) found on the surface of melanoma cells 
and destroy them.26 The genes encoding T-cell receptors (TCR) that are specific for a variety of 
TAA have now been cloned and are being utilized in treatment. These TCRs have been shown to 
react to approximately 50% of cancers arising from common epithelial origins (which Dudley et 
al. and colleagues observed).  
Adoptive cell therapy (ACT) has emerged as the most promising treatments for patients 
with metastatic melanoma. ACT-based immunotherapy was first described in 1988,27 but the 
decisive improvement in efficacy came in 2002 with the introduction of an immunodepleting 
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preparative regimen given before the adoptive transfer. This treatment adjunct improved the 
repopulation of the patient’s anti-tumor T cells.28 Of patients with MMM refractory to all other 
treatments, 50% experienced an objective response, some with complete responses.29 Recent 
studies demonstrating that normal human lymphocytes can be genetically engineered to 
recognize cancer antigens and to mediate cancer regression in vivo, has opened doors for 
enhancing and extending the ACT approach to patients with a wide variety of cancer types.30  
This breakthrough researcher brings up the clinical question: Is there a benefit to 
treatment with ACT following lymphodelpleting chemotherapy for the treatment of patients with 
refractory metastatic melanoma? 
Materials and Methods 
A comprehensive literature search was employed by utilizing the following internet 
databases and websites:  Ovid:Medline, Pub Med, The Journal of Clinical Oncology, and the 
National Institutes of Health. The keywords: Adoptive cell transfer, melanoma, treatment, and 
chemotherapy were entered for search purposes. 
Inclusion criteria considered were literature, in the English language, from January 1999 
to present was focused upon for the determination of ACT therapy. Those articles chosen were 
compiled and analyzed to determine relevance to addressing the clinical question.  
Studies which incorporated animal subjects, vaccine administration, myeloablative 
chemotherapy, and interferon administration were excluded. Clinical trials prior to January 1999 
were also excluded. Studies not published in English were not utilized. Jadad score was applied 
to each article, but little benefit was observed due to the nature of the clinical trial design. 
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Results 
Four articles, published 2002-2008, were the subject of this review to determine 
risk/benefit and overall survival of treatment with ACT/chemotherapy for patients with MMM. 
These articles afforded the opportunity to draw a conclusion as to the future of ACT therapy. 
A phase I clinical trial using non-myeloablative, lymphodepleting chemotherapy in 
combination with adoptive immunotherapy in patients with MMM. The chemotherapy-
conditioning schedule that induced transient lymphopenia consisted of cyclophosphamide (30 or 
60 mg/kg per day for 2 days) followed by fludarabine (25 mg/m2 per day for 5 days). 
Immunotherapy for all patients consisted of in vitro expanded, tumor-reactive, autologous T-cell 
clones selected due to their ability to recognize melanoma surface antigens. Cohorts of three to 
six patients each received either no interleukin (IL)-2, low-dose IL-2 (72,000 IU/kg 
intravenously three times a day to a maximum of 15 doses), or high-dose IL-2 (720,000 IU/kg 
intravenously three times a day for a maximum of 12 doses). The toxicities associated with this 
treatment were transient and included neutropenia and thrombocytopenia that resolved in all 
patients. Interestingly, administration of high dose intravenous IL-2 was better tolerated by 
patients after chemotherapy than during previous immunotherapy cycles without chemotherapy. 
The results revealed that not one of the fifteen patients exhibited an objective clinical 
response to treatment, although five patients demonstrated mixed responses or transient 
shrinkage of metastatic tumors. These findings led the researchers to believe that cellular 
persistence may be an extremely important component to effective treatment. Dudley et al. and 
colleagues established that a non-myeloablative conditioning regimen could be safely 
administered in conjunction with ACT and IL-2 in patients with metastatic melanoma.  
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The research trial which stimulated medical community awareness in ACT was published 
on April 1, 2005 in the Journal of Clinical Oncology. The primary research coordinator was 
Mark E. Dudley in conjunction with the National Institutes of Health (NIH). This team 
conducted a follow-up study to the one they had conducted in 2002. The trial investigated the 
combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous 
tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma. 
The study trial consisted of thirty-five patients with MM, all but one with disease refractory to 
treatment with high-dose interleukin (IL-2), and many with progressive disease after 
chemotherapy. These subjects underwent lymphodepleting conditioning with two days of 
cyclophosphamide (60mg/kg) followed by five days of fludarabine (25 mg/m2). The day 
following the final dose of fludaranbine, all patients received cell infusion with autologous 
tumor-reactive, rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-2 
therapy. 
The results of this treatment regimen resulted in eighteen of thirty five (51%) patients 
experiencing objective clinical responses which included three ongoing complete responses and 
fifteen partial responses with a mean duration of 11.5 +/- 2.2 months. Sites of regression 
included, metastases to lung, liver, lymph nodes, brain, and cutaneous and subcutaneous tissues. 
Toxicities of treatment included the hematologic toxicities of chemotherapy including 
neutropenia, thrombocytopenia, and lymphopenia (the transient toxicities of high-dose IL-2 
therapy). Two patients developed Pneumocystis pneumonia, and one patient developed an 
Epstein-Barr virus–related lymphoproliferation. The research team concluded the 
lymphodepleting chemotherapy followed by the transfer of highly aggressive antitumor 
lymphocytes (ACT) can mediate significant tumor regression in heavily pretreated patients with 
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IL-2 refractory MM. Although the study’s findings showed statistically significant results, the 
administration of IL-2 was also shown to produce systemic toxicities, which complicated the 
patient’s prognosis. 
 Another follow-up study published in May 2008, conducted by the NIH, focused upon 
the ACT of genetically engineered TILs which produced IL-2 with the promising conclusion that 
this method of therapy would be just as efficacious as the previously used high dose supplement 
of IL-2, without the toxic effects to the patients (Dudley et al. and colleagues 2008). 
Thirteen patients received non-myeloablative, lymphodepleting chemotherapy, as 
previously described by Dudley et al. 2005, consisting of two days of cyclophosphamide (60 
mg/kg) followed by five days of fludarabine (25 mg/m2). One day after the final dose, patients 
received IL-2-transduced TILs via intravenous infusion over thirty minutes. From this point in 
the trial, the patients were randomly split into three cohorts to receive slightly different therapy 
to determine the efficacy of supplemental IL-2. In cohort I, TILs from three patients were 
transduced twice (using 3 × 106 cells per well), followed by one rapid expansion with OKT3 
antibody (30 ng/ml; Ortho Biotech, Bridgewater, NJ), a 200-fold excess of irradiated (4000 rad) 
allogeneic feeder PBMCs, and IL-2 (6000 IU/ml) in 50/50 medium [50% CM mixed with 50% 
AIM-V (Invitrogen)], which typically resulted in a 1000-fold expansion in fourteen days.  
In cohort II, the five patient’s TILs were transduced during days seven and eight of the 
first rapid expansion (using 3 × 106 cells per well) followed by a second expansion to obtain 
sufficient cell numbers for treatment. Patients in cohorts I and II did not receive exogenous IL-2. 
The remaining five patients in cohort III were TIL transduced on days three and four of the first 
expansion (using 1 × 106 cells per well), followed by a second expansion, and the patients in this 
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cohort did receive concomitant high-dose IL-2 injections (720,000 IU/kg intravenously) every 
eight hours until tolerance developed.  
The outcomes of this study were slightly discouraging with only two patients who 
exhibited partial response up to four to six months (one patient from cohort II and one patient 
from cohort III). Because TILs are mainly CD8+ T cells, which have a much lower capacity for 
IL-2 secretion, the need for CD4+ T cell help (Janssen et al., 2003; Antony et al., 2005; Williams 
et al., 2006) might be circumvented in part by endowing the CD8+ T cell with IL-2 production. 
The authors deduced that the low response rate was due to factors involved with the genetic 
engineering of the TILs. 
A study conducted by the NIH, published in October of 2006, reached success in the use 
and application of immunotherapy through the ACT of lymphocytes after host immunodepletion. 
The researchers determined that, it could be possible to mediate objective cancer regression in 
human patients with MMM. This study was headed by Richard A. Morgan and Mark E. Dudley, 
whose team was able to report the ability to specifically confer tumor recognition by autologous 
lymphocytes from peripheral blood by using a retrovirus that encodes a TCR, specifically the 
MART-1 TCR. All 17 patients selected had progressive MMM, refractory to previous therapy 
with IL-2. 
The patients in this study were divided into three cohorts and received ACT with varying 
ex vivo culture periods. One goal of the study was to determine if the growth phase and culture 
periods had an effect on cell persistence in vivo. The other, was to determine treatment response. 
The three patients in Cohort I were administered ACT following nineteen days of ex vivo culture. 
These patients displayed poor cell persistence in vivo, and no tumor response was noted in any 
patient. Ten patients in Cohort II received ACT following six to eight day of ex vivo culture. All 
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patients had evidence of cell persistence upwards of ninety days. Unfortunately, only one patient 
had a response to treatment, and it was only a partial response. The third cohort consisted of four 
patients who were administered ACT following eighteen days of ex vivo culture with the addition 
of a rapid expansion protocol. This group also showed MART-1 CTLs at greater than ninety 
days post administration, but again only one patient displayed any clinical response to treatment. 
All clinical responses were judged by Response Evaluation Criteria in Solid Tumors (RECIST).  
Adoptive transfer of the transduced cells in 14 patients resulted in durable engraftment at 
levels exceeding 10% of peripheral blood lymphocytes for at least two months after the infusion. 
They observed high sustained levels of circulating, engineered cells at one year after infusion in 
2 patients who both demonstrated objective regression of MMM lesions. No toxicities in any 
patient could be attributed to the modified CTLs or ACT protocol. 
Patient 4 (cohort II), a 52-year-old male, had previously received treatment with 
interferon-α (IFN-α), a lymph node dissection, an experimental vaccine, and high-dose IL-2. The 
patient then developed progressive disease in the liver and axilla. After treatment with the ACT 
protocol, he experienced complete regression of the axillary mass and an 89% reduction of the 
liver mass, at which time it was removed. He remained clinically disease-free at twenty one 
months after treatment. Patient 14 (cohort III), a 30-year-old male, previously had received 
treatment consisting of a lymph node dissection, IFN-α, and high-dose IL-2. He developed an 
enlarging mass in the lung hilum. After ACT treatment, his hilar mass regressed and he remained 
clinically disease-free at 20 months post. Thus, two patients with rapidly progressive metastatic 
melanoma showed full clinical regression of disease after the transfer of genetically engineered 
autologous PBLs, which delighted Dudley et al. and colleagues. 
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 A clinical trial published in October of 2000 by Cassian Yee et al. and colleagues 
inspected a current strategy for immunotherapy in treating MMM. The focused treatment of this 
study incorporated the augmentation of the immune response to tumor antigens represented by 
TCR proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting 
of tumor antigens representing normal proteins can result in autoimmune toxicity has been 
postulated but never demonstrated. 
In this study, a single patient with MMM developed inflammatory lesions 
(circumscribed, pigmented areas of skin) after an infusion of MART-1–specific CD8+ T cell 
clones. Analysis of the TILs in skin and tumor biopsies using T cell–specific peptide–major 
histocompatibility complex (MHC) tetramers demonstrated a localized predominance of MART-
1–specific CD8+ T cells (>28% of all CD8 T cells) that was identical to the infused clones. In 
contrast to skin biopsies obtained from the patient before T cell infusion, post-infusion tissue 
biopsies demonstrated the loss of MART-1 expression, evidence of melanocyte damage, and the 
complete absence of melanocytes in affected regions of the skin. Yee et al. and colleagues 
provided, for the first time, direct evidence that antigen-specific immunotherapy can target not 
only antigen-positive tumor cells in vivo but also normal tissues expressing the shared tumor 
antigen. 
Discussion 
Currently there are no US FDA approved ACT therapies. Although within the last 
decade, there has been an explosion of knowledge in genetics, biochemistry, immunology, and 
oncology. The new approaches being made will revolutionize cancer therapy as did the advent of 
transfusion medicine.  
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Adoptive transfer therapy with TILs requires the isolation of T cells from fresh patient 
biopsy specimens, and the progressive selection of tumor-specific T cells ex vivo using high 
levels of IL-2 and various cell culture approaches. The adoptive transfer of these cells showed 
promise in preclinical models,31 but clinical experiences, with perhaps one exception,32 were 
almost uniformly disappointing. However, recent studies at the National Cancer Institute suggest 
that prior host conditioning with chemotherapy increases the response to adoptive 
immunotherapy with TILs. Unfortunately, in the absence of a randomized clinical trial, it is not 
possible to determine how much lymphoablative chemotherapy, high-dose IL-2 administration, 
and TIL therapy contributed to the promising results in these recent trials conducted by Dudley 
et al. and colleagues, 2005. 
Technical issues with the production of tumor-specific T cells currently present a 
formidable barrier to conducting randomized clinical trials using TILs. Only 30%–40% of biopsy 
specimens yield satisfactory T cell populations, and the process is labor, cost, and time intensive, 
requiring about 6 weeks to produce the T cells for infusion. These obstacles were reported by 
Dudley et al. and colleagues, 2003. Therefore, randomized trials based on a rigorous intent-to-
treat analysis (in which all data from all patients are included in the data analysis and any 
patients who are discontinued or otherwise non-evaluable are considered to be treatment failures) 
cannot be performed using currently available tissue culture technologies.  The trials reported to 
date, and in this review, have been performed based on an ad hoc, as-treated analysis plan. It is 
also important to mention, nearly all clinical trials with TILs have involved patients with MMM 
because of the surgical availability of tumor biopsy tissue. However, when the limitations of 
current tissue culture technology are overcome, this therapeutic approach shows great promise in 
impacting the survival of those afflicted with epithelial cancers. 
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To answer the clinical question: Is there a benefit to treatment with ACT following 
lymphodelpleting chemotherapy for the treatment of patients with refractory metastatic 
melanoma? Following review of the outcomes generated from the four clinical trials, this 
question remains difficult to answer. The ability to have the continuity of researchers involved, 
and relatively the same methods, made this topic interesting to examine. The future of this 
particular form of treatment looks very promising, but currently the response statistics are low. 
The patients must take into account quality of life, whether to spend his or her last days as 
chosen, or dedicate a substantial amount of time to treatment in a clinical atmosphere which may 
or may not prolong his or her life.  
Conclusion 
 In a time where restrictions on stem-cell research are being lifted, the hope for cure and 
improved treatment for those suffering from chronic and terminal illness continues to grow. The 
capacity to study stem cells will certainly allow insight into our ability to manipulate cellular 
activity, growth, and death.  
The goal of this review was to educate the reader about the clinical trials of ACT for the 
treatment of MMM. This knowledge is based on lymphocyte and cancer biology, which has only 
begun to crest the horizon in recent years. Nevertheless, lessons can be learned from previous 
trials which failed to achieve their clinical goal. Like all of medicine, there has always been a 
process of trial and error, proof and cure. Given time to overcome technological and logistical 
obstacles, immunotherapy will be at the forefront of successful cancer treatment in the very near 
future.   
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TABLE  I:  The ABCD Checklist for Detecting Cutaneous Melanoma  
 
Checklist item  
 
Reassuring elements  
 
Non-reassuring elements  
 
A = Asymmetry 
Suggestive of melanoma if the 
lesion is bisected and the halves 
are not identical 
 
Symmetric (benign) 
 
Asymmetric (malignant 
melanoma) 
B = Border irregularity 
Suggestive of melanoma if the 
border is uneven or ragged 
 
Borders are even (benign) 
 
Borders are irregular (malignant 
melanoma) 
C = Color variation 
Suggestive of melanoma if there is 
more than one shade of pigment  
 
One shade/even color (benign) 
 
Two or more shades/uneven 
color (malignant melanoma) 
D = Diameter 
Suggestive of melanoma if the 
diameter is greater than 6 mm 
 
Diameter <6 mm (benign) 
 
Diameter >6mm (malignant 
melanoma) 
 
NOTE: Biopsy should be strongly considered if one or more non-reassuring elements are present. 
 
* Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3d ed. St. Louis: Mosby, 
1996:898, and Goldstein BG, Goldstein AO. Practical dermatology. St. Louis: Mosby, 1992:132. 
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TABLE II:  Seven-Point Checklist for 
Suspected Malignant Melanoma  
 
Major signs*  
Change in size  
Change in shape  
Change in color  
Minor signs**  
Inflammation  
Crusting or bleeding  
Sensory change  
Diameter of 7 mm or more  
 
*--One or more major signs: refer for expeditious biopsy; 
additional presence of one or more minor signs increases 
the possibility of melanoma. 
**--Three or four minor signs without a major sign: 
consider referral. 
Information from Whited JD, Grichnik JM. Does this 
patient have a mole or a melanoma? JAMA 1998; 279:696-
701. 
 
 
 
TABLE III:  Breslow's Microstages and 
Clark's Levels for Melanoma  
 
Breslow's microstages  
 
Five-year survival 
(%)  
 
Stage 1: <0.76 mm >98 
Stage 2: 0.76 to 1.49 mm 87 to 94 
Stage 3: 1.50 to 3.99 mm 66 to 83 
Stage 4: >4.0 mm <50 
  
Clark's levels  
 
Five-year survival 
(%)  
 
Level I: Intraepidermal >99 
Level II: Extends into the 
papillary dermis 
95 
Level III: Fills the papillary 
dermis 
82 
Level IV: Extends into the 
reticular dermis 
71 
Level V: Invades the 
subcutaneous tissue 
49 
 
Information from Habif TP. Clinical dermatology: a 
color guide to diagnosis and therapy. 3d ed. St. 
Louis: Mosby, 1996:898, and Goldstein BG, 
Goldstein AO. Practical dermatology. St. Louis: 
Mosby, 1992:132.  
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Figure I:  Distribution of melanoma by body site and sex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Redrawn after Austoker J. Melanoma prevention and early diagnosis. BMJ 1994; 308:1682-6. 
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